View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Mahaut Arnaud ... (+3)
  • Mahaut Arnaud
  • Paul de Froment
  • Thomas Mordelle

Alfen: FY24 results, disappointing outlook

Yesterday, Alfen published FY24 revenues (down 3.3% YoY at EUR487.6m) broadly in line with consensus and BGe expectations (respectively EUR483.0m and EUR485.2m). Gross margin, however, came in at 23.7% (-6.3ppt vs. 30.0% in FY23) and was affected by significant one-off items whereas adjusted EBITDA

Wim Hoste
  • Wim Hoste

DSM-Firmenich Feedback conference call

Below are the highlights from the 4Q24 results conference call. 4Q adj EBITDA jumped by 37% and was about 2% better than our and consensus forecasts. Dsm-firmenich guides for at least 13% adj. EBITDA growth in FY25, on the back of a combination of synergies, savings and continued benefit from temporary high vitamin prices. The company is still looking to exit the ANH business and, reflecting the strong balance sheet, has announced a € 1bn share buyback program. We still appreciate dsm-firmenich ...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ackermans & van Haaren: Acquisition of boutique wealth manager Petram & Co. Alfen: Takes care of costs and debt, guidance misses. Arcadis: Solid backlog growth provides comfort. BAM: A friend of ours, 10% yield. CM.com: 2H24 results – FCF positive, capital restructuring. dsm-firmenich: Cash in, cash back. Flow Traders: Roller Coaster. KBC: Encouraging outlook to 2027, poor dividend. RELX: FY24 results – in line, £1.5bn buyback in 2025. Talabat: A beat at its maiden 4Q24 results...

Kristof Samoy
  • Kristof Samoy

Arcadis Clear beat on EBITA and margins, FCF slightly weaker, nice bol...

FY24 net revs grew 4.5% org. to €3880m (vs. our €3901m and css of €3914m). Operating EBITA landed at €447m (vs. our €435m and css of € 443m) discounting an 11.5% margin up from 10.4% in FY23. The backlog rose to €3673m up 16.3% organically y/y. 4Q order intake of €998m was particularly strong in Resilience & Places with overall book-to-bill ratio of 1.04x down from 1.3x in 3Q24. However the latter quarter experienced exceptional order intake in Mobility. A €1 dps (€0.95 est.) is proposed.

Sharad Kumar S.P
  • Sharad Kumar S.P

Ackermans & van Haaren Delen Private Bank Deepens Presence In The Neth...

Enter Private Bank has reached an agreement to acquire 100% of Petram & Co., an asset manager based in Utrecht, Netherlands. This is Delen's 6th acquisition (over the last 9 years) in the Netherlands since it entered the Dutch market in 2016 with the acquisition of Oyens & Van Eeghen. While we do welcome the news of Delen's growth, we are not entirely surprised. AvH management, over the last 2 years, has already mentioned that for the Private Banking Division, the Netherlands offers sufficient o...

Hilde Van Boxstael ... (+9)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ACKB BB, ADYEN NA, ARCAD NA, DSFIR NA, EXM BB, FLOW NA...

: ACKB BB, ADYEN NA, ARCAD NA, DSFIR NA, EXM BB, FLOW NA, GLPG NA, SIP BB, ALFEN NA

Martijn Den Drijver
  • Martijn Den Drijver
Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
Jacob Mekhael
  • Jacob Mekhael

Galapagos FY24 update outlines path to market for lead CAR-T

Galapagos reported FY24 results which came with a pipeline prioritisation providing clarity on the path to market lead program GLPG5101 (CD19 CAR-T). With pivotal development planned for 2026 in 8 B-cell malignancies and a first approval targeted for 2028, Galapagos' CAR-T plans are shaping up. YE24 cash came in at € 3.3b and Galapagos will have 500m following the business split announced in January, sufficient to fund the company to reach its next inflection milestones and we expect renewed int...

Wim Hoste
  • Wim Hoste

DSM-Firmenich FIRST LOOK: 4Q adj EBITDA +37%, FY25 guidance of at leas...

4Q adj EBITDA jumped by 37% and was about 2% better than our and consensus forecasts. Dsm-firmenich guides for at least 13% adj. EBITDA growth in FY25, on the back of a combination of synergies, savings and continued benefit from temporary high vitamin prices. The company is still looking to exit the ANH business and, reflecting the strong balance sheet, has announced a € 1bn share buyback program. We still appreciate dsm-firmenich for its broad portfolio and market leading positions. The upcomi...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures
 PRESS RELEASE

Arcadis Q4 and Full Year 2024 Results: Record earnings per share, reco...

Arcadis Q4 and Full Year 2024 Results: Record earnings per share, record backlog, enhanced long term visibility PRESS RELEASE | Arcadis Fourth Quarter and Full Year Results 2024 Record earnings per share, record backlog, enhanced long term visibility FOURTH QUARTER Strong Order Intake of €1.0 billion resulting in Book to Bill of 1.04xRecord fourth quarter operating EBITA margin of 12.6% (Q4‘23: 11.4%)Free Cash Flow generation of €183 million (Q4‘23: €208 million)Bolt-on acquisition of Data Center Design business in Germany FULL YEAR Record backlog of €3.7 billion, organic growt...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch